Biotechnology

Canadian biotech Satellos Bioscience seeks a Nasdaq listing and a $50M public offering to advance its promising muscle regeneration drug for Duchenne.

Early trial data for ABX1100 reveals a novel approach to reducing muscle damage in Pompe disease, offering hope for less burdensome treatment.

Viking Therapeutics' upcoming earnings call is about more than just financials. Investors are focused on key pipeline updates for its obesity and MASH drugs.

With a new focus on eye disease and fresh funding, Surrozen will present its novel Wnt-based pipeline to investors. What's at stake for the future of sight?

After a blockbuster IPO raised nearly $300 million, dermatologist-founded Veradermics is poised to challenge the hair loss market with its new oral pill.

The biotech celebrates its first FDA drug approval, a massive financial boost, and promising new therapies targeting obesity and Alzheimer's disease.

A new drug from Bayer dramatically cuts recurrent stroke risk by 26% without the dangerous bleeding side effects of current therapies, offering hope to millions.

With a massively oversubscribed bond sale and upgraded credit ratings, Italian API giant FIS solidifies its finances to expand in a booming pharma market.

A top engineering prize honors John Donoghue for BrainGate, a technology that lets the mind control machines, offering new hope for paralysis and ALS.

New data reveals Orca-T cell therapy boosts survival and cuts complications in blood cancer, as the company prepares for a potential FDA approval this year.

A new initiative unites top scientists to study 'SuperAgers' and resilient brains, aiming to unlock the secrets of healthy aging and prevent Alzheimer's.

The Rainwater Foundation awards $600,000 to pioneering scientists, accelerating breakthroughs in treating devastating neurodegenerative tauopathies.

TransCode Therapeutics and Quantum Leap are targeting hidden cancer cells with a novel RNA drug in a pivotal trial that could prevent colorectal cancer relapse.

With backing from top VCs, Angitia Biopharmaceuticals is accelerating its novel treatments for osteoporosis and rare bone disorders. Here's why it matters.

A new study reveals Exicure's burixafor mobilizes stem cells in one hour, promising to streamline cancer treatment and unlock future gene therapies.

With major drug approvals on the horizon, Nuvalent's leadership will detail its strategy for its next-gen cancer therapies at an influential investor summit.

VectorY Therapeutics adds seasoned biotech architect Kevin Pojasek to its board, signaling a strategic push to accelerate its novel therapies for ALS and Alzheimer's.

Insulet launches its tubeless Omnipod 5 insulin pump and new Discover data platform in the Middle East, offering a new lifeline for a region in need.

A new partnership will integrate data from millions in India and the UAE, aiming to fix research bias and build more equitable AI-driven medicine.

Positive study results for Alvotech's Entyvio biosimilar could disrupt the IBD market, promising lower costs for a blockbuster chronic care treatment.